Precipio, Inc., a specialty cancer diagnostics company, has reached an agreement with its largest warrant holder to amend the structure of warrant exercise. Approximately 100,000 warrants will be exercised with cash, while the remaining 200,000 warrants will be exercised in a cashless manner. This transaction will reduce the number of outstanding shares by approximately 130,000-150,000 and bring in around $1.2 million in cash. The company will provide further details on this transaction during its upcoming quarterly shareholder call on or around August 15th, 2025. Precipio focuses on developing cancer diagnostic solutions to improve accuracy, laboratory workflow, and patient outcomes. Investors can find more information on Precipio’s website and social media channels.

Read more at GlobeNewswire: Precipio Enters Into Agreement With Warrant Holder To